Cynosure Enhances Industry-Leading Smartlipo Family with 1440 nm Wavelength

New Smartlipo Triplex(TM) Laser Lipolysis Workstation Delivers Higher
Absorption of Fatty Tissue with Same Powerful Tissue Coagulation and
Tightening Effect

WESTFORD, Mass., Oct. 22 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq:
CYNO), a leading developer and manufacturer of a broad array of light-based
aesthetic treatment systems, today announced the introduction of Smartlipo
Triplex(TM), the world's first laser lipolysis solution featuring three
wavelengths that combine to deliver high-powered fat absorption and tissue
tightening through tissue coagulation. Smartlipo Triplex will be formally
launched at Plastic Surgery 2009, the American Society of Plastic Surgeons
Annual Meeting, which will be held October 23-27 in Seattle.

Smartlipo Triplex adds a 1440 nm wavelength to the MPX generation of the
product, and employs Cynosure's patented MultiPlex technology to combine the
benefits of three wavelengths in one laser output. MultiPlex technology
enables two wavelengths to be fired sequentially, creating a blended thermal
and photomechanical effect that efficiently liquefies fat and tightens skin
through collagen remodeling.

"With 20 times greater absorption in fatty tissue than any other single
wavelength on the market, the 1440 nm wavelength puts Smartlipo in a new
class," said Barry DiBernardo, M.D., Medical Director of New Jersey Plastic
Surgery & MedNet Technologies, Inc. in Montclair, NJ. "Combining the
photomechanical effects of the 1440 nm with the 1064 nm wavelength results in
even greater disruption of fatty tissue for faster and deeper treatments than
the 1064 wavelength alone. At the same time, the Smartlipo Triplex continues
to deliver unmatched tissue tightening through tissue coagulation by blending
the 1064 and 1320 nm wavelengths."

"We continue to advance our Smartlipo family of products to address the
demands of the marketplace: faster and greater absorption of fat,
high-definition body sculpting capabilities and tissue tightening through
tissue coagulation," said Cynosure President and Chief Executive Officer
Michael Davin. "We believe that Smartlipo Triplex enables medical
professionals to deliver the most accurate combination therapy available today
by providing a superior mix of energy levels and wavelengths. Whether
treating a small well-defined area or removing larger amounts of fatty tissue,
Smartlipo Triplex offers doctors the ability to customize the treatment to
achieve maximum results. At the same time, we believe our safety features are
unmatched in the industry."

Smartlipo Triplex is equipped with SmartSense with ThermaGuide, the latest in
Cynosure's proprietary family of intelligent energy delivery systems.
SmartSense with ThermaGuide is designed to work in harmony with the laser. It
continually detects the temperature under the skin and controls the output of
energy. This helps to ensure that the treatment area remains within a safe
and optimal temperature range for fat removal and tissue tightening through
tissue coagulation.

"Smartlipo Triplex is the technology of choice for my body sculpting
procedures," said John Millard, M.D., a board-certified plastic surgeon based
in Denver. "It allows for quick and efficient removal of fat without excess
heat - a requirement for high-definition results."

About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used
by physicians and other practitioners to perform non-invasive and minimally
invasive procedures to remove hair, treat vascular and pigmented lesions,
rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis
and temporarily reduce the appearance of cellulite. Cynosure's products
include a broad range of laser and other light-based energy sources, including
Alexandrite, pulse dye, Nd:YAG and diode lasers, as well as intense pulsed
light. Cynosure was founded in 1991. For corporate or product information,
contact Cynosure at 800-886-2966, or visit www.cynosure.com.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and
prospects for Cynosure, Inc., including statements about expectations for its
new Smartlipo Triplex as well as other statements containing the words
"believes," "anticipates," "plans," "expects," "will" and similar expressions,
constitute forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a result
of various important factors, including the global economic recession and its
effects on the aesthetic laser industry, Cynosure's history of operating
losses, its reliance on sole source suppliers, the inability to accurately
predict the timing or outcome of regulatory decisions, changes in consumer
preferences, competition in the aesthetic laser industry, economic, market,
technological and other factors discussed in Cynosure's most recent Annual
Report on Form 10-K and Quarterly Report on Form 10-Q, which are filed with
the Securities and Exchange Commission. In addition, the forward-looking
statements included in this press release represent Cynosure's views as of the
date of this press release. Cynosure anticipates that subsequent events and
developments will cause its views to change. However, while Cynosure may
elect to update these forward-looking statements at some point in the future,
it specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing Cynosure's views as of
any date subsequent to the date of this press release.

Contact:

Scott Solomon
Vice President
Sharon Merrill Associates, Inc.
617-542-5300
cyno@investorrelations.com

SOURCE Cynosure, Inc.

Scott Solomon, Vice President of Sharon Merrill Associates, Inc.,
+1-617-542-5300, cyno@investorrelations.com